Kate Haviland, Blueprint Medicines CEO

Blue­print met all its end­points in bid for ex­pand­ed Ay­vak­it la­bel — but stock trends low­er any­way

Blue­print Med­i­cines an­nounced this morn­ing that the sec­ond part of its study on Ay­vak­it in non-ad­vanced sys­temic mas­to­cy­to­sis (SM) — a rare dis­ease in which a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.